儿童白血病FHIT的mRNA表达研究

Study of the mRNA Expression of FHIT in Childhood Leukemia

【目的】了解脆性组氨酸三联体（fragile histidine triad，FHIT）基因在儿童白血病中的表达，分析FHIT基因与儿童白血病的关系；探讨FHIT基因在儿童白血病中的发病机制。【方法】收集本院2009年1月至2011年3月白血病的儿童51例作为白血病组，同期本院非白血病儿童10例作为对照组，检测两组儿童骨髓单个核细胞（Bone marrow mononuclear cells，BMMCs）中FHIT基因的mRNA表达。【结果】白血病组FHITmRNA表达阳性率明显低于对照组（54．90％VS100．00％，P〈0．05）；白血病缓解组FHITInRNA表达阳性率为66．67％，对照组FHITmRNA表达阳性率为100．00％，两组间无明显差异（P〉0．05）；白血病组FHITmRNA表达阳性率在不同性别、年龄、白血病类型、治疗阶段组别间无显著差异（P〉0．05）；高肿瘤负荷组FHITmRNA表达阳性率明显低于低肿瘤负荷组（33．33％VS66．67％，P〈0．05）。【结论】FHITmRNA在儿童白血病中低表达；FHITmRNA表达阳性率在不同性别、年龄、白血病类型、治疗阶段的白血病儿童间无差异；高肿瘤负荷的白血病患儿FHITmRNA表达阳性率低于低肿瘤负荷患儿。

[Objective]To understand the expression of fragile histidine triad（FHIT） in childhood leukemia, and to analyze the relationship between FHIT and childhood leukemia, and to explore the role of FHIT in the pathogene- sis of childhood leukemia. [Methods] A total of 51 pediatric patients with leukemia from Jan. 2009 to March 2011 were collected as leukemia group. Other 10 children without leukemia during the same period were collected from Hu- nan provincial people＇s hospital as the control group. The expression of FHIT mRNA in bone marrow mononuclear cells（BMMCs） of two groups was detected. [Results] The positive rate of FHIT mRNA in leukemia group was obvi ously lower than that in control group（54.9% vs 100.00%, P 〈0.05）. There was no significant difference in the positive rate of FHIT mRNA between leukemia remission group and control group（66. 67% vs 100. 00%, P〉 0.05）. There was no significant difference in the positive rate of FHIT mRNA among leukemia groups with different sex, age, leukemia type and treatment phase（ P 〉0. 05）. The positive rate of FHIT mRNA in high tumor load group was obviously lower than that in low tumor load group（33.33% vs 66.67%, P 〈0.05）. [Conclusion] Pediat- ric patients with leukemia have low expression of FHIT mRNA. There is no significant difference in the positive rate of FHIT mRNA among leukemia patients with different sex, age, leukemia type and treatment phase. The positive rate of FHIT mRNA in leukemia patients with high tumor load is lower than that in leukemia patients with low tumor load.